JP2008526933A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526933A5
JP2008526933A5 JP2007550826A JP2007550826A JP2008526933A5 JP 2008526933 A5 JP2008526933 A5 JP 2008526933A5 JP 2007550826 A JP2007550826 A JP 2007550826A JP 2007550826 A JP2007550826 A JP 2007550826A JP 2008526933 A5 JP2008526933 A5 JP 2008526933A5
Authority
JP
Japan
Prior art keywords
formulation
kit
tumor
somatostatin
somatostatin analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007550826A
Other languages
English (en)
Japanese (ja)
Other versions
JP5171262B2 (ja
JP2008526933A (ja
Filing date
Publication date
Priority claimed from GB0500807A external-priority patent/GB0500807D0/en
Priority claimed from GB0507811A external-priority patent/GB0507811D0/en
Priority claimed from PCT/GB2005/002217 external-priority patent/WO2005117830A1/en
Priority claimed from GB0518878A external-priority patent/GB0518878D0/en
Application filed filed Critical
Priority claimed from PCT/GB2005/004748 external-priority patent/WO2006075124A1/en
Publication of JP2008526933A publication Critical patent/JP2008526933A/ja
Publication of JP2008526933A5 publication Critical patent/JP2008526933A5/ja
Application granted granted Critical
Publication of JP5171262B2 publication Critical patent/JP5171262B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007550826A 2005-01-14 2005-12-09 ソマトスタチン類似体製剤 Expired - Lifetime JP5171262B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB0500807A GB0500807D0 (en) 2005-01-14 2005-01-14 Formulation
GB0500807.3 2005-01-14
GB0507811.8 2005-04-18
GB0507811A GB0507811D0 (en) 2005-04-18 2005-04-18 Formulation
PCT/GB2005/002217 WO2005117830A1 (en) 2004-06-04 2005-06-06 Liquid depot formulations
GBPCT/GB2005/002217 2005-06-06
GB0518878.4 2005-09-15
GB0518878A GB0518878D0 (en) 2005-09-15 2005-09-15 Formulations
PCT/GB2005/004748 WO2006075124A1 (en) 2005-01-14 2005-12-09 Somatostatin analogue formulations

Publications (3)

Publication Number Publication Date
JP2008526933A JP2008526933A (ja) 2008-07-24
JP2008526933A5 true JP2008526933A5 (enExample) 2009-02-05
JP5171262B2 JP5171262B2 (ja) 2013-03-27

Family

ID=40432504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550826A Expired - Lifetime JP5171262B2 (ja) 2005-01-14 2005-12-09 ソマトスタチン類似体製剤

Country Status (7)

Country Link
US (1) US8871712B2 (enExample)
EP (1) EP1843746B1 (enExample)
JP (1) JP5171262B2 (enExample)
AT (1) ATE501710T1 (enExample)
CA (1) CA2594711C (enExample)
DE (1) DE602005026998D1 (enExample)
PL (1) PL1843746T3 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
CN104093399B (zh) * 2011-12-05 2018-03-13 卡穆鲁斯公司 鲁棒性控释肽制剂
CN104080478A (zh) * 2012-01-31 2014-10-01 参天制药株式会社 非水性液体组合物
AU2013265210B2 (en) * 2012-05-25 2016-09-15 Camurus Ab Somatostatin receptor agonist formulations
AU2017336199B2 (en) * 2016-09-27 2020-08-20 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
WO2018067987A1 (en) * 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
CA3045114A1 (en) 2016-12-07 2018-06-14 Ra Pharmaceuticals, Inc. Modulators of complement activity
JP2021059680A (ja) * 2019-10-08 2021-04-15 花王株式会社 液晶組成物
CN113368041B (zh) * 2020-07-17 2023-01-03 丽珠医药集团股份有限公司 药物组合物、缓释制剂及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US595502A (en) * 1897-12-14 terpeningt
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
WO1993006921A1 (en) 1991-10-04 1993-04-15 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
CA2120359C (en) 1991-10-04 2000-12-26 Tomas Landh Particles, method of preparing said particles and uses thereof
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
AU685262B2 (en) 1994-03-30 1998-01-15 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
AU702030B2 (en) 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0975331A1 (en) 1997-04-17 2000-02-02 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
EP1600162A1 (en) 1998-12-22 2005-11-30 Eli Lilly & Company Shelf-stable formulation of glucagon-like peptide-1
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
CA2451432A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
WO2005014162A1 (en) 2003-08-04 2005-02-17 Camurus Ab Method for improving the properties of amphiphile particles
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
EP1682091B1 (en) 2003-11-07 2017-03-29 Camurus Ab Compositions of lipids and cationic peptides
WO2005063213A1 (en) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1713446B1 (en) 2004-01-23 2010-12-01 Camurus Ab Ternary non-lamellar lipid compositions
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
JP5513713B2 (ja) 2004-08-04 2014-06-04 カムルス エービー 非層状分散を生じる組成物
WO2006075123A1 (en) 2005-01-14 2006-07-20 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (es) 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
KR100983746B1 (ko) 2005-01-14 2010-09-24 카무러스 에이비 소마토스타틴 유사 제형
WO2006077362A1 (en) 2005-01-21 2006-07-27 Camurus Ab Pharmaceutical lipid compositions
CN101217940B (zh) 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
US8097239B2 (en) 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
WO2007061896A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations

Similar Documents

Publication Publication Date Title
Strosberg et al. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors
Lamberts et al. Octreotide
Susini et al. Rationale for the use of somatostatin analogs as antitumor agents
TWI624271B (zh) 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途
HRP20161500T1 (hr) Formulacije cikličkog somatostatina s polaganim otpuštanjem
Giustina et al. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors
CA2594711A1 (en) Somatostatin analogue formulations
JP2022058707A (ja) 薬剤送達デバイス
US20260000730A1 (en) Somatostatin receptor agonist formulations
Massironi et al. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules
ES2369155T3 (es) Combinación de análogos de somtostanina con diferente selectividad para subtipos de receptores de somatostatina humanos.
Fattah et al. Progress in the formulation and delivery of somatostatin analogs for acromegaly
Lauricella et al. The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives
Calnan et al. Potency and stability of C terminal truncated human epidermal growth factor
Öberg Somatostatin analog octreotide LAR® in gastro–entero–pancreatic tumors
Msaouel et al. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology
Roelfsema et al. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®
Tarasco et al. Effect of AP102, a subtype 2 and 5 specific somatostatin analog, on glucose metabolism in rats
Paragliola et al. Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors
Kyriakakis et al. Lanreotide autogel in acromegaly–a decade on
Al-Toubah et al. Somatostatin analogs and interferon in the treatment of neuroendocrine tumors
Gallmann et al. Effect of CCK-8 on insulin-induced hyperphagia and hypothalamic orexigenic neuropeptide expression in the rat
Rubio et al. Cortistatin as a therapeutic target in inflammation
Petersenn Efficacy and limits of somatostatin analogs
Panzuto et al. Unlabelled somatostatin analogues in treatment of digestive endocrine tumours